InvestorsHub Logo
Followers 89
Posts 2879
Boards Moderated 1
Alias Born 08/20/2010

Re: Norm post# 1184

Friday, 12/28/2012 6:44:23 PM

Friday, December 28, 2012 6:44:23 PM

Post# of 5932
APPA..APF530 targets a $900 million market opportunity in US alone

?Recent competitive setbacks could enhance commercial uptake

?Could be second, long-acting, injectable product on market

?In 2011, there were 5.1 million vials of injectable 5-HT3 antagonists administered for CINV

?The average selling price for market leader Aloxi is $175

APPA held end-of-review meetings with FDA in 1Q 2011

No additional clinical efficacy studies requested

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HRTX News